Fesoterodine Fumarate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Fesoterodine Fumarate |
| DrugBank ID | DB06702 |
| Brand Names (EU) | Toviaz |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.87% |
Approved Indication (EMA)
Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | overactive bladder (disease) | 98.87% | DL |
| 2 | polycystic kidney disease 3 with or without polycystic liver disease | 91.13% | DL |
| 3 | thoracic malformation | 89.92% | DL |
| 4 | renal-hepatic-pancreatic dysplasia | 89.64% | DL |
| 5 | Joubert syndrome with renal defect | 88.48% | DL |
| 6 | adult familial nephronophthisis-spastic quadriparesia syndrome | 88.42% | DL |
| 7 | karyomegalic interstitial nephritis | 87.34% | DL |
| 8 | low compliance bladder | 86.46% | DL |
| 9 | faciodigitogenital syndrome | 84.84% | DL |
| 10 | attention deficit-hyperactivity disorder | 82.44% | DL |
| 11 | polycystic kidney disease | 79.91% | DL |
| 12 | congenital analbuminemia | 74.64% | DL |
| 13 | hyperamylasemia | 72.90% | DL |
| 14 | polyclonal hyperviscosity syndrome | 72.90% | DL |
| 15 | restless legs syndrome | 67.53% | DL |
| 16 | communication disorder | 66.95% | DL |
| 17 | tic disorder | 66.20% | DL |
| 18 | developmental disorder of mental health | 65.77% | DL |
| 19 | stereotypic movement disorder | 64.96% | DL |
| 20 | fetal nicotine spectrum disorder | 64.96% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.